comprehensive -WSS

comprehensive

author：explore 2025-10-01 14:14:53 - browse：5

Adobe

A month after announcing it was seeking strategic alternatives, Akili Interactive, maker of a video game designed to treat ADHD, said it will go private in a merger with Virtual Therapeutics. The deal is expected to net Akili’s shareholders $34 million.

Akili made headlines in 2020 when it received Food and Drug Administration clearance for EndeavorRx, a video game designed to treat pediatric ADHD. Akili went public in 2022 in a deal that valued the company at about $1 billion. But despite several strategic pivots, including shifting to direct-to-consumer sales, the company failed to build a sustainable business model. Akili in April announced it would wind down its existing commercial operations and focus on a licensing deal with Japanese pharma company Shionogi while it figured out the best path forward.

Akili is just one of many health tech companies that are struggling following an explosion of investor interest in digital health during the Covid-19 pandemic. In the last month alone, Better Therapeutics, another company making digital treatments, sold its assets for an undisclosed amount after failing to build a business around its app for type 2 diabetes, and Cue Health, a diagnostics startup, shut down after funding interest in its Covid-19 tests evaporated.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Readout Newsletter: What happened with Sarepta's Duchenne data

Wikipedia

WSS

Paying for Covid pills will soon shift to insurers

In utero gene editing: an explainer

The pink breast cancer awareness ribbon needs a redesign

Dario to buy mental health app maker Twill in cash and stock deal

Why palliative psychiatry is worth discussing

FDA approves Eli Lilly ulcerative colitis treatment Omvoh

knowledge

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

hotspot

Psychedelics group wrestles with new pharma identity

Meta's Zuckerberg and Chan on track to put $50 billion into science

After affirmative action ruling, medical educators look to 'holistic review'

Cassava reveals details — and problems — with Alzheimer's study

Medical records are filled with copy

First Opinion Podcast: How to protect health care in times of war

Apple is now the first public company to be valued at $3 trillion

First Opinion Podcast: How to protect health care in times of war

Walensky prepares to leave CDC — and Congress — behind

Alabama hospital puts IVF treatments on hold

focus

An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

Obesity drugs seen as possible treatment for liver disease MASH

He's a Nobel laureate. Critics say he was misleading on Covid

He's a Nobel laureate. Critics say he was misleading on Covid

WHO may add ‘noma' to its list of neglected tropical diseases

CDC recommends rationing of RSV shot due to shortages

hotspot

Wikipedia

Wikipedia

Wikipedia